AJP - Heart AJP: Lung Cellular and Molecular Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 288: H328-H335, 2005. First published September 2, 2004; doi:10.1152/ajpheart.00453.2004
0363-6135/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
288/1/H328    most recent
00453.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Das, S.
Right arrow Articles by Das, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Das, S.
Right arrow Articles by Das, D. K.

Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation

Samarjit Das, Gerald A. Cordis, Nilanjana Maulik, and Dipak K. Das

Cardiovascular Research Center, University of Connecticut School of Medicine, Farmington, Connecticut

Submitted 25 May 2004 ; accepted in final form 28 July 2004

Recent studies demonstrated that resveratrol, a grape-derived polyphenolic phytoalexin, provides pharmacological preconditioning (PC) of the heart through a NO-dependent mechanism. Because adenosine receptors play a role in PC, we examined whether they play any role in resveratrol PC. Rats were randomly assigned to groups perfused for 15 min with 1) Krebs-Henseleit bicarbonate buffer (KHB) only; 2) KHB containing 10 µM resveratrol; 3) 10 µM resveratrol + 1 µM 8-cyclopentyl-1,3-dimethylxanthine (CPT; adenosine A1 receptor blocker); 4) 10 µM resveratrol + 1 µM 8-(3-chlorostyryl)caffeine (CSC; adenosine A2a receptor blocker); 5) 10 µM resveratrol + 1 µM 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(±)-dihydropyridine-3,5-dicarboxylate (MRS-1191; adenosine A3 receptor blocker); or 6) 10 µM resveratrol + 3 µM 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride [LY-294002, phosphatidylinositol (PI)3-kinase inhibitor], and groups perfused with adenosine receptor blockers alone. Hearts were then subjected to 30-min ischemia followed by 2-h reperfusion. The results demonstrated significant cardioprotection with resveratrol evidenced by improved ventricular recovery and reduced infarct size and cardiomyocyte apoptosis. CPT and MRS 1191, but not CSC, abrogated the cardioprotective abilities of resveratrol, suggesting a role of adenosine A1 and A3 receptors in resveratrol PC. Resveratrol induced expression of Bcl-2 and caused its phosphorylation along with phosphorylation of cAMP response element-binding protein (CREB), Akt, and Bad. CPT blocked phosphorylation of Akt and Bad without affecting CREB, whereas MRS 1191 blocked phosphorylation of all compounds, including CREB. LY-294002 partially blocked the cardioprotective abilities of resveratrol. The results indicate that resveratrol preconditions the heart through activation of adenosine A1 and A3 receptors, the former transmitting a survival signal through PI3-kinase-Akt-Bcl-2 signaling pathway and the latter protecting the heart through a CREB-dependent Bcl-2 pathway in addition to an Akt-Bcl-2 pathway.

Akt; cAMP response element-binding protein; Bad; apoptosis



Address for reprint requests and other correspondence: D. K. Das, Cardiovascular Research Center, Univ. of Connecticut, School of Medicine, Farmington, CT 06030-1110 (E-mail: ddas{at}neuron.uchc.edu)




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. K. Mohan, M. Khan, S. Wisel, K. Selvendiran, A. Sridhar, C. A. Carnes, B. Bognar, T. Kalai, K. Hideg, and P. Kuppusamy
Cardioprotection by HO-4038, a novel verapamil derivative, targeted against ischemia and reperfusion-mediated acute myocardial infarction
Am J Physiol Heart Circ Physiol, January 1, 2009; 296(1): H140 - H151.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. K. Das and N. Maulik
Cardiac genomic response following preconditioning stimulus
Cardiovasc Res, May 1, 2006; 70(2): 254 - 263.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
D. K. Das and N. Maulik
Resveratrol in cardioprotection: a therapeutic promise of alternative medicine.
Mol. Interv., February 1, 2006; 6(1): 36 - 47.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.